ArriVent BioPharma Stock Plunges 54% on Disappointing Drug Trial Results
ArriVent BioPharma shares fell 54% to $13 on Tuesday, marking its largest single-day decline, following the release of disappointing results for its lung-cancer drug.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.